Michael E. Castagna serves as the Chief Executive Officer at MannKind Corporation, a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. With a strong background in pharmaceutical leadership, Castagna has been instrumental in guiding MannKind through significant growth and development since joining the company in 2017 as the Chief Commercial Officer before ascending to the CEO position in 2020. Prior to his tenure at MannKind, Castagna held several key leadership roles within the pharmaceutical industry. He notably served as Vice President and General Manager of AstraZeneca's U.S. Respiratory Business Unit, where he was responsible for the launch and growth of multiple blockbuster products. His strategic vision and deep understanding of market dynamics have been pivotal in his career, allowing him to drive commercial success and innovation. At MannKind, Castagna has been at the forefront of advancing the company's flagship product, Afrezza, an inhaled insulin for diabetes management, and expanding the company's pipeline to address other significant unmet medical needs. As CEO, Castagna continues to lead MannKind with a focus on patient-centric innovation and operational excellence. Under his leadership, the company has strengthened its commercial infrastructure, enhanced its research and development capabilities, and forged strategic partnerships to broaden its market reach. His commitment to improving patient outcomes and his ability to navigate complex industry challenges have solidified his reputation as a transformative leader in the biopharmaceutical sector.